Christopher Lieu
Concepts (363)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 41 | 2023 | 646 | 8.800 |
Why?
| Molecular Targeted Therapy | 9 | 2019 | 361 | 2.240 |
Why?
| Antineoplastic Agents | 14 | 2021 | 1990 | 2.170 |
Why?
| Biomarkers, Tumor | 16 | 2023 | 1076 | 2.150 |
Why?
| Colonic Neoplasms | 7 | 2023 | 230 | 2.130 |
Why?
| Rectal Neoplasms | 7 | 2023 | 122 | 1.960 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 1402 | 1.560 |
Why?
| Neoplasms | 11 | 2022 | 2235 | 1.250 |
Why?
| Drug Resistance, Neoplasm | 8 | 2019 | 673 | 1.180 |
Why?
| Immunotherapy | 4 | 2022 | 504 | 1.040 |
Why?
| Mutation | 12 | 2020 | 3493 | 0.990 |
Why?
| Vascular Endothelial Growth Factor A | 4 | 2020 | 537 | 0.960 |
Why?
| Oncologists | 1 | 2023 | 31 | 0.920 |
Why?
| Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 243 | 0.920 |
Why?
| Cetuximab | 4 | 2023 | 99 | 0.910 |
Why?
| Bevacizumab | 4 | 2020 | 127 | 0.900 |
Why?
| Gastrointestinal Neoplasms | 1 | 2023 | 62 | 0.880 |
Why?
| Antibodies, Monoclonal | 6 | 2023 | 1306 | 0.840 |
Why?
| Microsatellite Instability | 6 | 2022 | 31 | 0.800 |
Why?
| Neuroendocrine Tumors | 5 | 2022 | 91 | 0.780 |
Why?
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 658 | 0.750 |
Why?
| Neoplasm Staging | 11 | 2023 | 1234 | 0.750 |
Why?
| Age of Onset | 7 | 2022 | 479 | 0.720 |
Why?
| Piperidines | 2 | 2017 | 169 | 0.670 |
Why?
| Humans | 81 | 2023 | 122796 | 0.660 |
Why?
| Colectomy | 1 | 2019 | 89 | 0.660 |
Why?
| Early Detection of Cancer | 2 | 2022 | 364 | 0.640 |
Why?
| Cyclosporine | 1 | 2018 | 175 | 0.630 |
Why?
| Terminology as Topic | 1 | 2019 | 217 | 0.610 |
Why?
| Azetidines | 1 | 2017 | 29 | 0.610 |
Why?
| Benzimidazoles | 1 | 2018 | 142 | 0.610 |
Why?
| Disease-Free Survival | 7 | 2023 | 661 | 0.600 |
Why?
| Appendiceal Neoplasms | 2 | 2020 | 14 | 0.590 |
Why?
| Pancreatic Neoplasms | 6 | 2023 | 803 | 0.580 |
Why?
| Genetic Predisposition to Disease | 4 | 2022 | 2359 | 0.580 |
Why?
| Healthcare Disparities | 1 | 2021 | 494 | 0.540 |
Why?
| Adrenal Gland Neoplasms | 3 | 2022 | 82 | 0.530 |
Why?
| MAP Kinase Kinase Kinases | 1 | 2015 | 71 | 0.530 |
Why?
| Patient Rights | 1 | 2015 | 10 | 0.530 |
Why?
| Pyrimidinones | 1 | 2015 | 88 | 0.520 |
Why?
| Therapies, Investigational | 1 | 2015 | 15 | 0.520 |
Why?
| Drug and Narcotic Control | 1 | 2015 | 27 | 0.520 |
Why?
| Drugs, Investigational | 1 | 2015 | 31 | 0.510 |
Why?
| Precision Medicine | 1 | 2019 | 371 | 0.510 |
Why?
| Medical Oncology | 4 | 2023 | 231 | 0.510 |
Why?
| Pyridones | 1 | 2015 | 120 | 0.500 |
Why?
| Neovascularization, Pathologic | 2 | 2013 | 292 | 0.500 |
Why?
| Adenocarcinoma | 5 | 2023 | 837 | 0.480 |
Why?
| Wnt Signaling Pathway | 1 | 2015 | 153 | 0.480 |
Why?
| Pyrazines | 2 | 2018 | 79 | 0.470 |
Why?
| Immunoglobulin G | 1 | 2017 | 804 | 0.450 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 187 | 0.450 |
Why?
| Proto-Oncogene Proteins B-raf | 4 | 2020 | 204 | 0.440 |
Why?
| Middle Aged | 30 | 2022 | 28563 | 0.440 |
Why?
| Drug Design | 1 | 2013 | 163 | 0.440 |
Why?
| ErbB Receptors | 5 | 2017 | 571 | 0.430 |
Why?
| Neoadjuvant Therapy | 5 | 2023 | 348 | 0.420 |
Why?
| Terminal Care | 1 | 2015 | 186 | 0.420 |
Why?
| Neoplasm Metastasis | 7 | 2022 | 563 | 0.410 |
Why?
| Carcinoma, Signet Ring Cell | 1 | 2011 | 3 | 0.410 |
Why?
| Circulating Tumor DNA | 2 | 2022 | 23 | 0.410 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 320 | 0.400 |
Why?
| Fibroblast Growth Factors | 1 | 2011 | 180 | 0.370 |
Why?
| Aged | 23 | 2022 | 20495 | 0.370 |
Why?
| Adult | 27 | 2022 | 32385 | 0.370 |
Why?
| src-Family Kinases | 1 | 2010 | 109 | 0.350 |
Why?
| Stomach Neoplasms | 3 | 2022 | 70 | 0.350 |
Why?
| Patient Selection | 3 | 2019 | 717 | 0.340 |
Why?
| Fluorouracil | 4 | 2022 | 160 | 0.330 |
Why?
| Health Services Accessibility | 1 | 2015 | 813 | 0.330 |
Why?
| Disease Management | 4 | 2021 | 591 | 0.320 |
Why?
| Boronic Acids | 1 | 2008 | 43 | 0.320 |
Why?
| Janus Kinase 2 | 1 | 2008 | 32 | 0.320 |
Why?
| Etoposide | 1 | 2008 | 149 | 0.320 |
Why?
| Carboplatin | 1 | 2008 | 142 | 0.320 |
Why?
| Myeloproliferative Disorders | 1 | 2008 | 27 | 0.320 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2021 | 747 | 0.310 |
Why?
| Clinical Decision-Making | 3 | 2019 | 293 | 0.310 |
Why?
| Genomics | 3 | 2022 | 714 | 0.300 |
Why?
| Male | 30 | 2022 | 59639 | 0.300 |
Why?
| Kaplan-Meier Estimate | 6 | 2017 | 884 | 0.300 |
Why?
| Pathology, Clinical | 2 | 2017 | 34 | 0.300 |
Why?
| Pathology, Molecular | 2 | 2017 | 26 | 0.290 |
Why?
| Shock, Septic | 1 | 2009 | 213 | 0.290 |
Why?
| Chemotherapy, Adjuvant | 4 | 2023 | 369 | 0.290 |
Why?
| Female | 30 | 2022 | 63629 | 0.290 |
Why?
| Drug Administration Schedule | 4 | 2019 | 757 | 0.280 |
Why?
| ras Proteins | 2 | 2017 | 142 | 0.270 |
Why?
| Clinical Trials as Topic | 3 | 2015 | 985 | 0.270 |
Why?
| Age Factors | 5 | 2021 | 3114 | 0.260 |
Why?
| Diagnosis, Differential | 1 | 2009 | 1423 | 0.250 |
Why?
| Metastasectomy | 1 | 2023 | 13 | 0.230 |
Why?
| United States | 12 | 2021 | 13272 | 0.230 |
Why?
| Clinical Trials, Phase II as Topic | 2 | 2022 | 58 | 0.230 |
Why?
| Trifluridine | 1 | 2022 | 3 | 0.230 |
Why?
| Signal Transduction | 6 | 2018 | 4902 | 0.230 |
Why?
| Ovarian Neoplasms | 2 | 2020 | 460 | 0.220 |
Why?
| Camptothecin | 3 | 2022 | 100 | 0.220 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2022 | 75 | 0.220 |
Why?
| Disease Models, Animal | 4 | 2021 | 3799 | 0.220 |
Why?
| Genetic Testing | 3 | 2022 | 400 | 0.220 |
Why?
| Microsatellite Repeats | 1 | 2022 | 147 | 0.210 |
Why?
| Survival Rate | 6 | 2023 | 1810 | 0.210 |
Why?
| Membrane Proteins | 3 | 2019 | 1093 | 0.210 |
Why?
| Chemoradiotherapy, Adjuvant | 2 | 2023 | 42 | 0.210 |
Why?
| Incidence | 6 | 2022 | 2527 | 0.200 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 31 | 0.200 |
Why?
| Neoplasms, Multiple Primary | 1 | 2022 | 57 | 0.200 |
Why?
| Health Status Disparities | 2 | 2020 | 217 | 0.200 |
Why?
| Pheochromocytoma | 1 | 2022 | 54 | 0.200 |
Why?
| DNA | 1 | 2008 | 1401 | 0.190 |
Why?
| Capecitabine | 2 | 2022 | 46 | 0.190 |
Why?
| Meningioma | 1 | 2022 | 82 | 0.190 |
Why?
| Heterografts | 1 | 2021 | 132 | 0.190 |
Why?
| Congresses as Topic | 2 | 2019 | 208 | 0.190 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 228 | 0.190 |
Why?
| Practice Patterns, Physicians' | 1 | 2009 | 1267 | 0.190 |
Why?
| Treatment Outcome | 10 | 2021 | 9692 | 0.180 |
Why?
| Consensus | 2 | 2019 | 554 | 0.180 |
Why?
| Immune System | 1 | 2021 | 184 | 0.180 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 17 | 0.180 |
Why?
| Smad4 Protein | 1 | 2019 | 38 | 0.170 |
Why?
| Area Under Curve | 2 | 2018 | 303 | 0.170 |
Why?
| GTP Phosphohydrolases | 1 | 2019 | 69 | 0.170 |
Why?
| Prognosis | 8 | 2023 | 3563 | 0.170 |
Why?
| Retinal Vein | 1 | 2019 | 13 | 0.170 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 82 | 0.170 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2022 | 466 | 0.170 |
Why?
| Cell-Free Nucleic Acids | 1 | 2019 | 28 | 0.170 |
Why?
| Disease Progression | 4 | 2017 | 2546 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 1981 | 0.170 |
Why?
| B7-H1 Antigen | 1 | 2020 | 151 | 0.170 |
Why?
| Neoplasm Grading | 1 | 2019 | 265 | 0.160 |
Why?
| Vasculitis | 1 | 2019 | 75 | 0.160 |
Why?
| Genes, ras | 1 | 2018 | 99 | 0.160 |
Why?
| Young Adult | 4 | 2023 | 11094 | 0.160 |
Why?
| Survivorship | 1 | 2018 | 38 | 0.160 |
Why?
| Drug Combinations | 2 | 2022 | 292 | 0.160 |
Why?
| Retinal Diseases | 1 | 2019 | 81 | 0.160 |
Why?
| Risk Factors | 6 | 2022 | 9381 | 0.160 |
Why?
| Cohort Studies | 6 | 2020 | 5294 | 0.160 |
Why?
| Proportional Hazards Models | 3 | 2017 | 1184 | 0.160 |
Why?
| Neoplasm Transplantation | 1 | 2018 | 248 | 0.160 |
Why?
| Patient Advocacy | 1 | 2018 | 71 | 0.160 |
Why?
| Asthenia | 1 | 2017 | 1 | 0.160 |
Why?
| Acneiform Eruptions | 1 | 2017 | 1 | 0.160 |
Why?
| Neoplasm Recurrence, Local | 2 | 2023 | 903 | 0.160 |
Why?
| Population Surveillance | 1 | 2021 | 439 | 0.150 |
Why?
| Risk Assessment | 2 | 2019 | 3213 | 0.150 |
Why?
| Esophageal Neoplasms | 1 | 2021 | 287 | 0.150 |
Why?
| Evidence-Based Medicine | 2 | 2019 | 731 | 0.150 |
Why?
| Drug Eruptions | 1 | 2017 | 28 | 0.150 |
Why?
| Hypokalemia | 1 | 2017 | 31 | 0.150 |
Why?
| Patient Compliance | 1 | 2021 | 561 | 0.150 |
Why?
| Receptor, ErbB-3 | 1 | 2017 | 42 | 0.150 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2019 | 202 | 0.150 |
Why?
| Imidazoles | 1 | 2018 | 234 | 0.150 |
Why?
| MAP Kinase Kinase 1 | 1 | 2017 | 67 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 201 | 0.150 |
Why?
| Biomarkers | 3 | 2023 | 3662 | 0.150 |
Why?
| Aged, 80 and over | 7 | 2021 | 6845 | 0.150 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 373 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2019 | 159 | 0.150 |
Why?
| Digestive System Neoplasms | 1 | 2016 | 7 | 0.150 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2019 | 164 | 0.140 |
Why?
| Retrospective Studies | 9 | 2023 | 13433 | 0.140 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 288 | 0.140 |
Why?
| Cell Line, Tumor | 3 | 2022 | 2904 | 0.140 |
Why?
| Time Factors | 2 | 2019 | 6682 | 0.140 |
Why?
| Biliary Tract Neoplasms | 1 | 2015 | 20 | 0.140 |
Why?
| Edema | 1 | 2016 | 130 | 0.140 |
Why?
| Hospitals | 1 | 2021 | 633 | 0.140 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 57 | 0.140 |
Why?
| Databases, Factual | 3 | 2017 | 1287 | 0.140 |
Why?
| Diabetic Neuropathies | 1 | 2016 | 100 | 0.140 |
Why?
| Animals | 9 | 2021 | 34133 | 0.130 |
Why?
| Patient Care Planning | 1 | 2016 | 143 | 0.130 |
Why?
| Device Approval | 1 | 2015 | 24 | 0.130 |
Why?
| Neuralgia | 1 | 2016 | 115 | 0.130 |
Why?
| Delivery of Health Care, Integrated | 1 | 2018 | 247 | 0.130 |
Why?
| Analgesics | 1 | 2016 | 163 | 0.130 |
Why?
| Prevalence | 1 | 2022 | 2442 | 0.130 |
Why?
| Leucovorin | 3 | 2022 | 45 | 0.130 |
Why?
| Receptor, Notch1 | 1 | 2015 | 65 | 0.130 |
Why?
| Immunoblotting | 1 | 2015 | 318 | 0.130 |
Why?
| Pancreas | 1 | 2017 | 295 | 0.130 |
Why?
| Deoxycytidine | 1 | 2015 | 141 | 0.130 |
Why?
| Health Behavior | 1 | 2020 | 731 | 0.130 |
Why?
| Gene Dosage | 1 | 2015 | 139 | 0.130 |
Why?
| Immunoconjugates | 1 | 2016 | 90 | 0.130 |
Why?
| Administration, Oral | 1 | 2017 | 786 | 0.130 |
Why?
| Drug Approval | 1 | 2015 | 80 | 0.130 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 167 | 0.120 |
Why?
| Quinazolines | 1 | 2015 | 243 | 0.120 |
Why?
| Phenotype | 2 | 2021 | 3070 | 0.120 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 186 | 0.120 |
Why?
| Genetic Variation | 1 | 2019 | 952 | 0.120 |
Why?
| Liver Neoplasms | 1 | 2018 | 546 | 0.120 |
Why?
| Cancer Survivors | 1 | 2018 | 225 | 0.120 |
Why?
| Spinal Cord Injuries | 1 | 2016 | 184 | 0.120 |
Why?
| beta Catenin | 1 | 2015 | 223 | 0.120 |
Why?
| Delivery of Health Care | 1 | 2021 | 915 | 0.120 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1260 | 0.120 |
Why?
| Proto-Oncogene Proteins | 1 | 2017 | 646 | 0.120 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 783 | 0.110 |
Why?
| Lymphocytes | 1 | 2015 | 360 | 0.110 |
Why?
| Patient-Centered Care | 1 | 2018 | 513 | 0.110 |
Why?
| Registries | 1 | 2021 | 2020 | 0.110 |
Why?
| Protein Kinase Inhibitors | 1 | 2018 | 833 | 0.110 |
Why?
| Angiogenesis Inhibitors | 1 | 2013 | 223 | 0.100 |
Why?
| Patient Care Team | 1 | 2016 | 520 | 0.100 |
Why?
| Ligands | 1 | 2013 | 582 | 0.100 |
Why?
| Risk | 1 | 2014 | 890 | 0.100 |
Why?
| Prospective Studies | 3 | 2022 | 6704 | 0.100 |
Why?
| Neoplasm, Residual | 2 | 2022 | 104 | 0.100 |
Why?
| Lung Neoplasms | 1 | 2023 | 2216 | 0.090 |
Why?
| Protein-Tyrosine Kinases | 1 | 2013 | 442 | 0.090 |
Why?
| Transcriptome | 1 | 2015 | 774 | 0.090 |
Why?
| Streptococcaceae | 1 | 2009 | 2 | 0.090 |
Why?
| Patient Satisfaction | 1 | 2013 | 632 | 0.090 |
Why?
| Cytokines | 2 | 2015 | 1928 | 0.090 |
Why?
| Clinical Medicine | 1 | 2009 | 21 | 0.090 |
Why?
| Apoptosis | 3 | 2022 | 2532 | 0.090 |
Why?
| Neutrophils | 1 | 2015 | 1246 | 0.090 |
Why?
| Chemoradiotherapy | 2 | 2023 | 201 | 0.080 |
Why?
| Myositis | 1 | 2009 | 41 | 0.080 |
Why?
| Sulindac | 1 | 2008 | 18 | 0.080 |
Why?
| Bortezomib | 1 | 2008 | 49 | 0.080 |
Why?
| Taiwan | 1 | 2008 | 19 | 0.080 |
Why?
| Mutation Rate | 2 | 2019 | 25 | 0.080 |
Why?
| Maximum Tolerated Dose | 1 | 2008 | 186 | 0.080 |
Why?
| Nausea | 1 | 2008 | 110 | 0.080 |
Why?
| Combined Modality Therapy | 1 | 2011 | 1174 | 0.080 |
Why?
| Mice | 4 | 2021 | 15888 | 0.080 |
Why?
| Neutropenia | 1 | 2008 | 134 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2008 | 201 | 0.080 |
Why?
| Fluphenazine | 1 | 2007 | 5 | 0.080 |
Why?
| Risperidone | 1 | 2007 | 27 | 0.080 |
Why?
| Multivariate Analysis | 3 | 2017 | 1531 | 0.080 |
Why?
| Exons | 1 | 2008 | 310 | 0.070 |
Why?
| Nerve Fibers, Myelinated | 1 | 2007 | 48 | 0.070 |
Why?
| Drug Therapy, Combination | 1 | 2010 | 988 | 0.070 |
Why?
| Anemia | 1 | 2008 | 156 | 0.070 |
Why?
| Food | 1 | 2008 | 164 | 0.070 |
Why?
| Fasting | 1 | 2008 | 266 | 0.070 |
Why?
| Gastrectomy | 2 | 2017 | 85 | 0.070 |
Why?
| Thrombocytopenia | 1 | 2008 | 188 | 0.070 |
Why?
| Frontal Lobe | 1 | 2007 | 152 | 0.070 |
Why?
| Postoperative Complications | 1 | 2017 | 2301 | 0.070 |
Why?
| Propensity Score | 2 | 2017 | 253 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2008 | 1021 | 0.060 |
Why?
| Antipsychotic Agents | 1 | 2007 | 197 | 0.060 |
Why?
| Adolescent | 3 | 2020 | 18948 | 0.060 |
Why?
| Survival Analysis | 2 | 2017 | 1325 | 0.060 |
Why?
| Oxidative Stress | 1 | 2010 | 1204 | 0.060 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 20 | 0.060 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.060 |
Why?
| Organoplatinum Compounds | 1 | 2022 | 41 | 0.060 |
Why?
| Endothelial Growth Factors | 1 | 2022 | 55 | 0.060 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 64 | 0.050 |
Why?
| Radioisotopes | 1 | 2022 | 36 | 0.050 |
Why?
| Gallium Radioisotopes | 1 | 2022 | 19 | 0.050 |
Why?
| Receptors, Peptide | 1 | 2022 | 24 | 0.050 |
Why?
| Intestinal Neoplasms | 1 | 2022 | 24 | 0.050 |
Why?
| Radionuclide Imaging | 1 | 2022 | 134 | 0.050 |
Why?
| Carcinoembryonic Antigen | 1 | 2022 | 40 | 0.050 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 29 | 0.050 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 71 | 0.050 |
Why?
| North America | 1 | 2022 | 271 | 0.050 |
Why?
| Europe | 1 | 2022 | 369 | 0.050 |
Why?
| Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| Radiopharmaceuticals | 1 | 2022 | 196 | 0.050 |
Why?
| Preventive Medicine | 1 | 2021 | 41 | 0.050 |
Why?
| Canada | 1 | 2022 | 355 | 0.050 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 78 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 66 | 0.050 |
Why?
| Liquid Biopsy | 1 | 2020 | 6 | 0.050 |
Why?
| Hyaluronic Acid | 1 | 2022 | 203 | 0.050 |
Why?
| National Cancer Institute (U.S.) | 1 | 2020 | 43 | 0.050 |
Why?
| Positron-Emission Tomography | 1 | 2022 | 308 | 0.050 |
Why?
| Mice, SCID | 1 | 2021 | 339 | 0.050 |
Why?
| Geography | 1 | 2020 | 199 | 0.050 |
Why?
| Morbidity | 1 | 2021 | 309 | 0.050 |
Why?
| SEER Program | 1 | 2020 | 206 | 0.050 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 228 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 588 | 0.040 |
Why?
| Sulfonamides | 1 | 2022 | 455 | 0.040 |
Why?
| Spectrophotometry, Infrared | 1 | 2019 | 54 | 0.040 |
Why?
| District of Columbia | 1 | 2018 | 28 | 0.040 |
Why?
| Karnofsky Performance Status | 1 | 2018 | 36 | 0.040 |
Why?
| Fluorescein Angiography | 1 | 2019 | 103 | 0.040 |
Why?
| DNA Mismatch Repair | 1 | 2018 | 29 | 0.040 |
Why?
| Colon | 1 | 2020 | 241 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2019 | 536 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 115 | 0.040 |
Why?
| Multimodal Imaging | 1 | 2019 | 102 | 0.040 |
Why?
| Tomography, Optical Coherence | 1 | 2019 | 134 | 0.040 |
Why?
| Delphi Technique | 1 | 2018 | 170 | 0.040 |
Why?
| Half-Life | 1 | 2017 | 147 | 0.040 |
Why?
| American Medical Association | 1 | 2017 | 21 | 0.040 |
Why?
| Genome, Human | 1 | 2019 | 392 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 668 | 0.040 |
Why?
| Genomic Instability | 1 | 2017 | 39 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 2017 | 191 | 0.040 |
Why?
| Needles | 1 | 2016 | 59 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2017 | 396 | 0.040 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 128 | 0.040 |
Why?
| Health Services Needs and Demand | 1 | 2018 | 265 | 0.040 |
Why?
| Meta-Analysis as Topic | 1 | 2017 | 172 | 0.030 |
Why?
| Retreatment | 1 | 2016 | 72 | 0.030 |
Why?
| Molecular Diagnostic Techniques | 1 | 2017 | 94 | 0.030 |
Why?
| Platinum | 1 | 2016 | 38 | 0.030 |
Why?
| Incidental Findings | 1 | 2016 | 82 | 0.030 |
Why?
| Acute Disease | 1 | 2019 | 984 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 390 | 0.030 |
Why?
| Jagged-1 Protein | 1 | 2015 | 25 | 0.030 |
Why?
| Serrate-Jagged Proteins | 1 | 2015 | 30 | 0.030 |
Why?
| Tumor Microenvironment | 1 | 2019 | 457 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 472 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 543 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 522 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3264 | 0.030 |
Why?
| Gene Duplication | 1 | 2015 | 66 | 0.030 |
Why?
| Radiography | 2 | 2016 | 888 | 0.030 |
Why?
| Endoscopy, Digestive System | 1 | 2016 | 114 | 0.030 |
Why?
| Protein Isoforms | 1 | 2016 | 347 | 0.030 |
Why?
| Preoperative Care | 1 | 2017 | 342 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2022 | 1519 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 309 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2737 | 0.030 |
Why?
| Societies, Medical | 1 | 2018 | 741 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2015 | 222 | 0.030 |
Why?
| Analysis of Variance | 1 | 2017 | 1329 | 0.030 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 715 | 0.030 |
Why?
| Brain Neoplasms | 1 | 2021 | 1016 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2016 | 421 | 0.030 |
Why?
| Ultraviolet Rays | 1 | 2016 | 413 | 0.030 |
Why?
| Behavior, Animal | 1 | 2016 | 486 | 0.030 |
Why?
| Skin | 1 | 2016 | 694 | 0.030 |
Why?
| Logistic Models | 1 | 2017 | 1995 | 0.030 |
Why?
| Follow-Up Studies | 1 | 2020 | 4768 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2016 | 1727 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 2501 | 0.020 |
Why?
| Protein Binding | 1 | 2016 | 2010 | 0.020 |
Why?
| Lung | 1 | 2023 | 3830 | 0.020 |
Why?
| Angiogenesis Inducing Agents | 1 | 2009 | 24 | 0.020 |
Why?
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 62 | 0.020 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2008 | 83 | 0.020 |
Why?
| Rats | 1 | 2016 | 5426 | 0.020 |
Why?
| Reference Standards | 1 | 2008 | 177 | 0.020 |
Why?
| Quality of Life | 1 | 2018 | 2457 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2008 | 151 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 5020 | 0.020 |
Why?
| Breast Neoplasms | 1 | 2019 | 1994 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2008 | 493 | 0.020 |
Why?
| Infusions, Intra-Arterial | 1 | 1986 | 46 | 0.020 |
Why?
| Hepatic Artery | 1 | 1986 | 56 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2500 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2011 | 1947 | 0.020 |
Why?
| Tandem Mass Spectrometry | 1 | 2008 | 423 | 0.020 |
Why?
| Reference Values | 1 | 2007 | 789 | 0.020 |
Why?
| Image Processing, Computer-Assisted | 1 | 2007 | 739 | 0.010 |
Why?
| Longitudinal Studies | 1 | 2007 | 2599 | 0.010 |
Why?
|
|
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|